Avicanna Inc · TSX:AVCN
Avicanna — Investor Presentation (July 2023)
24 slides from Avicanna's investor presentation, July 2023
Slide 1: Driving Biopharmaceutical Advancements
Q3 2023 Driving Biopharmaceutical Advancements of Naturally Derived and Evidence Based Products TSX: AVCN OTCQX: AVCNF FSE: 0NN avicanna.com © 2023 Avicanna Inc.
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain statements contained in this presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute “forward-looking statements” within the meaning of Canadian securities legislation and regulations and other applicable sec
Slide 3: Timeline
0.1 Timeline Avicanna is a commercial and scale-up stage biopharmaceutical company established in R&D, and commercialization of evidence-based cannabinoid products for the international consumer, medical and pharmaceutical market segments. Supported by its Canadian scientific platform, Avicanna has
Slide 4: Investment Highlights
0.2 Investment Highlights An International Medical and Biopharmaceutical Strategy • Five active business pillars: Medical cannabis products, Pharmacy platform, Cosmetics, API* and Pharmaceutical pipeline • Addressing the global market: International footprint with completed transactions in 19 countr
Slide 5: Avicanna's Five Business Pillars
0.3 Avicanna’s Five Business Pillars Intellectual Property and Brands Owned by Avicanna Medical Cannabis and Pharmaceutical Pipeline Medical Cannabis Wellness Products In Development and Pharmacy Platform Commercial Registration Stages Launching August 2023 Cosmetics and Active Skincare Pharmaceutic
Slide 6: Scientific Platform
1. Scientific Platform R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products © 2023 Avicanna Inc.
Slide 7: Established Scientific Platform
1.1 Established Scientific Platform 30+ 10+ Proprietary Scientists Commercial Products R&D through several Health 7 Canada issued Cannabis Pending Patents Research Licenses 11 Commercial Stage Canadian Government Advanced Drug Delivery Research Grants Systems Products Awarded Since 2020 07 © 2023 Av
Slide 8: World-Class Institutional Collaborations
1.2 World-Class Institutional Collaborations 20+ R&D, Pre-Clinical Studies and Collaborations with Canada’s Leading Institutions since 2017 08 © 2023 Avicanna Inc.
Slide 9: Commercial Products & Pipeline
2. Commercial Products & Pipeline Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products © 2023 Avicanna Inc.
Slide 10: RHO Phyto
Transdermal Gel Capsules Water-Soluble Tablets Infusers Local Creams Sublingual Spray 2.1 RHO Phyto Oil Drops Advanced Drug Delivery System Formulations (CBD, THC, CBG) - for International Medical and Wellness Market Segments © 2023 Avicanna Inc.
Slide 11: RHO Phyto and Medical Cannabis
2.1.1 RHO Phyto and Medical Cannabis Advanced Drug Evidence-based with Long-term Stability Accurate Dosing Advanced Pre-clinical & Accurate & Easy Delivery Platforms Delivery Pre-clinical Clinical Data Studies & Consistency Consistent Dosing & Easy to Use to Use • Successful proof of concept with ma
Slide 12: Proof of Concept and Partnership with Medical Cannabis by Shoppers
2.1.2 Succesful Proof of Concept and Partnership with Medical Cannabis by Shoppers Avicanna X Medical Cannabis by Shoppers Partnership, since 2019 • 23 commercial SKUs across 4 brands, strategic commercial and clinical partnership • Successful segmentation medical patients and aging population Natio
Slide 13: Canadian Commercialization Infrastructure
2.1.3 Canadian Commercialization Infrastructure National Medical Channels Provincial Adult Use Channels 25 4 61 6 113 Proprietary commercial National medical Commercial listings Provincial adult use Total commercial listings SKUs across 4 brands cannabis portals offering across medical channels, cha
Slide 14: MyMedi.ca - Medical Cannabis Care Platform
2.2.1 MyMedi.ca - Medical Cannabis Care Platform Established Through Acquisition from Medical Cannabis by Shoppers* MyMedi.ca MEDICAL CANNABIS CARE • Nationwide medical cannabis pharmacy • Multi-brand and diverse marketplace • Delivering an evidence-driven formulary of medical cannabis marketplace •
Slide 15: Medical Cannabis Education and Training
2.2.2 Medical Cannabis Education and Training A federally-registered Canadian non-profit A resource for health care professionals that are organization of basic and clinical researchers, health interested in learning more about the use and care professionals and educators that promote prescription o
Slide 16: Pharmaceutical Pipeline and Drug Candidates
2.3.1 Pharmaceutical Pipeline and Drug Candidates Designed to Address 5 Major Clinical Areas Sleep Eczema/ Pain Anxiety & Epilepsy Epidermolysis Management Depression Bullosa • Candidates are in various stages of R&D, pre-clinical to real world evidence studies and or registration stage • Leveraging
Slide 17: Trunerox 10% CBD
2.3.2 TruneroxTM 10% CBD (100 mg/ml Cannabidiol) Pharmaceutical Drug Preparation Pending Market Authorization • Pharmaceutical preparation under GMP standards with proprietary formulation with enhanced absorption • Expected marketing authorization during late 2023 in Brazil and other South American
Slide 18: Pura H&W: Clinically Backed CBD Dermacosmetic Products
2.4 Pura H&W: Clinically Backed CBD Dermacosmetic Products Functional Skin Care Products Addressing Global Emerging CBD Consumer Product Segment • Proprietary and patent-pending line of 13 premium topical products • Clinically backed first line of CBD topical products supported by clinical results (
Slide 19: Aureus Santa Marta: Cannabinoids and Standardized Genetics
2.5 Aureus Santa Marta: Cannabinoids and Standardized Genetics Avicanna’s Supply Chain Business Unit and Vertical Integration Raw Material Business Unit Branded as Aureus Santa Marta • Avicanna’s low cost and consistent supply of cannabinoids for its finished products through in-house cultivation an
Slide 20: Avicanna Around the World
2.6 Avicanna Around the World Completed Sales and Exports into 19 Countries MyMedi.ca MEDICAL CANNABIS CARE 20 © 2023 Avicanna Inc.
Slide 21: Financial & Capital Overview
3. Financial & Capital Overview Highlights Common shares: 86M* Tightly held by insiders and strategic investors TSX: AVCN 200% Revenue growth between Q1-2023 to Q2 2023** R&D and Pharmaceutical issuer on the TSX senior exchange since IPO in 2019 OTCQX: FSE: AVCNF 0NN *As of Market Close July 4th, 20
Slide 22: Management and Board of Directors
3.1 Management and Board of Directors Senior Management Team Board of Directors Aras Azadian Aras Azadian Founder and CEO Founder and CEO Phillip Cardella Dr. Chandra Panchal, PhD Chief Financial Officer Independant Director, Chair Stephen Kim Eileen McCormack Chief Legal Officer & General Counsel I
Slide 23: Corporate Highlights
3.2 Corporate Highlights De-risked investment - commercial stage, with key regulatory approvals and milestones achieved, with several product lines Diversified - scalable and high margin revenue streams Experienced management - proven track record since 2016 Intellectual property powerhouse - indust
Slide 24: Thank You
THANK YOU © 2023 Avicanna Inc.